Progress in treating Inflammatory Bowel Disease (IBD) is not linear. Landmark advances often start with a simple observation, an unusual idea or a question lacking sufficient preliminary evidence to attract major funding. Supporting this kind of research is one of the quieter but most essential roles a scientific society can play.
The portfolio of studies funded by the ECCO Research Grants illustrates this clearly. These projects cover a range of topics that are central to contemporary IBD research. Some focus on disease fundamentals underlying pathogenesis—like how the gut virome interacts with the immune system, how dendritic cells exert their function in this microenvironment, the role of metabolites produced from gut bacteria in the regulation of oxidative stress and the purpose of Paneth cells in intestinal homeostasis. Others look at areas that have recently entered the mainstream of IBD interest, such as the gut–brain axis and the delicate signalling between nerves and immune cells.
What matters more is that the programme goes beyond just the elucidation of mechanisms. It also includes research into questions derived from everyday clinical practice. Can we use biomarkers to find out who will develop IBD before symptoms appear? Can intestinal ultrasound tell us within weeks whether a patient will respond to treatment? Could transperineal ultrasound provide a simpler and faster way to assess perianal Crohn’s Disease? Could molecular signatures eventually provide the necessary framework for optimal treatment selection, thereby avoiding reliance on trial and error?
There is another aspect of this initiative that is worth emphasising. The value of research grants should not be judged only according to whether the original hypothesis turns out to be correct. Good research sometimes leads to a surprise finding, requires a methodological detour or raises a better question than the one with which it started. Several of the projects in this collection are still evolving, while others have already generated manuscripts, conference presentations and peer-reviewed publications. That process—from an idea, to experimental work, to dissemination—is precisely what research funding should enable.
Perhaps the deepest value of the ECCO Research Grant initiative lies not in the discoveries but in building a space where doctors and scientists can pursue questions across disciplines, institutions and countries—all connected by a specific problem: IBD.
This diversity is powerful. The problem of IBD will not be solved by one breakthrough. Instead, progress will rely on understanding how genetics, immunity, microbes, gut lining function, environmental factors and treatments interact in each person. To achieve this, ECCO will support and invest in discovery, driven by one overriding aim: the improvement of our patients’ lives.
